“We expect to grow between 10 and 15%”

The year Eurofarma turns 35 years, Maria Del Pilar Muñoz, Corporate Marketing director of the company, has several reasons to celebrate, like the great company performance last year, when R$ 940 million were invested in drugs, 26% more than in 2005. Such rate made the company grow more than the 7% expected by the company, according to information from Grupemef.

During an interview to Top Team, the executive said that such figures were reached mainly due to the performance of some departments of the company, like medical prescription and generics. Follow the main parts of the interview below:


Top Team: In 2007, Eurofarma turns 35 years. What´s your conclusion about it?

Maria Del Pilar Muñoz: Its consolidation in the market, the recognition of the serious and committed work of the company. Besides, the team´s work, their effort and the challenge that moves the company. The results reflect the satisfaction of our contributors and all their great contribution makes the company reach higher goals.


Top Team: Nowadays Eurofarma manufactures nearly 80 million units. Do you intend to increase such goal for the next years? How?

Maria Del Pilar Muñoz: The new Eurofarma industry – in Itapevi – was partially inaugurated in March, but it will be totally finished by the second semester of 2008. Such entrepreunership will cost around R$ 250 million and it might multiply its current production capacity. The aim is that this new industry meets the local needs of expansion and also the internationalization process of the company, becoming the productive polo of Eurofarma to supply Latin American and European countries, at first.


Top Team: Eurofarma ended 2006 with 26% of sales higher than the previous year. How did the company achieve such figure?

Maria Del Pilar Muñoz: Mainly due to the performance of the main departments of the company, such medical prescription and generics. Besides, the company invested substantially to reach such goals, like increasing the number of sales reps and also new products development. The amount of products brought into market by the company also contributed to sales increase besides its participation in markets where the company didn´t use to participate entirely or aggressively.


Top Team: What´s Eurofarma position about fractioned drugs ?

Maria Del Pilar Muñoz: the company already produces some fractioned items and some of them are about to be registered. If those drugs advance in the market, Eurofarma will be able to meet such demand.


Top Team: To wrap up, what´s the company expectation for 2007?

Maria Del Pilar Muñoz: We expect to grow between 10 and 15% in sales (revenue), that is, adding all the expected sales from all business units of the company; medical prescription, generics, hospital and bids, oncology, third parties and vet.